# A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells

> **NCT00703222** · PHASE1,PHASE2 · COMPLETED · sponsor: **Baylor College of Medicine** · enrollment: 7 (actual)

## Conditions studied

- Neuroblastoma

## Interventions

- **BIOLOGICAL:** SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 1 SKNLP
- **BIOLOGICAL:** SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 2 SKNLP

## Key facts

- **NCT ID:** NCT00703222
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2011-05
- **Final completion:** 2025-05
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2025-07-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00703222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00703222, "A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00703222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*